Prostate Cancer Study Moves to Phase IICBLI reported recently that its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer has progressed to the next phase.
“CBLC102 is the most advanced compound in our anti-cancer (Curaxin) pipeline and presents a significant and unique market opportunity as a potential oral therapy for cancer."
The Phase II study will involve a total of 31 patients with advanced, refractory prostate cancer. The dosing regimen includes a 300 mg loading dose three times daily for seven days, followed by a 100 mg maintenance dose administered once daily for an additional 23 weeks.
Primary endpoints for the study are reduction in PSA levels, reduction in tumor size, and disease-free survival.
The duration of the study is two years; however certain preliminary data may be available earlier.
The study is being conducted at the University of Chicago, the Cleveland Clinic and the University Hospitals of Cleveland.